Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

SOOD, ANIL K

One or more keywords matched the following items that are connected to SOOD, ANIL K

Item Type	Name
Academic Article	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Academic Article	Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Academic Article	Therapeutic advances in women's cancers.
Academic Article	Angiogenesis as a strategic target for ovarian cancer therapy.
Academic Article	Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
Academic Article	Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Academic Article	Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Academic Article	Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Academic Article	Contemporary use of bevacizumab in ovarian cancer.
Academic Article	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Academic Article	New ways to successfully target tumor vasculature in ovarian cancer.
Academic Article	Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
Academic Article	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Academic Article	Tumor T<inf>1</inf> relaxation time for assessing response to bevacizumab anti-angiogenic therapy in a mouse ovarian cancer model
Academic Article	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
Academic Article	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Concept	Bevacizumab
Academic Article	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.
Academic Article	Endothelial p130cas confers resistance to anti-angiogenesis therapy.
Academic Article	Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.
Academic Article	A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.

Search Criteria

Bevacizumab